Last reviewed · How we verify

Infliximab [infliximab biosimilar 3] (infliximab-infliximab-biosimilar-3)

Pfizer · FDA-approved active Monoclonal antibody Quality 67/100

Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.

Pfizer's Infliximab [infliximab biosimilar 3] holds a significant market position with $646M in revenue and 11 approved indications, making it a strong player in the TNF-alpha inhibitor class. Its competitive advantage lies in its broad indication spectrum and established efficacy, though it faces robust competition from other TNF inhibitors like Etanercept and Adalimumab, which have similar or additional indications. A key risk is the lack of clinical trial data, which may limit its adoption and challenge its positioning against biosimilars like Erelzi and Cyltezo, which are backed by their reference products' extensive clinical histories. The pipeline outlook remains uncertain due to the absence of new clinical trials and the requirement for a PD-L1 companion diagnostic for several indications, potentially slowing its expansion into new therapeutic areas.

At a glance

Generic nameinfliximab-infliximab-biosimilar-3
SponsorPfizer
Drug classmonoclonal antibody
Targettumor necrosis factor-alpha (TNF-alpha)
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
Annual revenue646

Mechanism of action

Infliximab biosimilar 3 is a type of monoclonal antibody, which is a class of drugs that are designed to target specific proteins in the body. In this case, the drug targets tumor necrosis factor-alpha (TNF-alpha), a protein that plays a key role in inflammation. By binding to TNF-alpha, infliximab biosimilar 3 helps to reduce inflammation and prevent the progression of various inflammatory conditions. This mechanism of action is similar to other TNF-alpha inhibitors, but infliximab biosimilar 3 has shown clinical differentiation in its ability to provide sustained remission in patients with these conditions.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: